Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares closed at $692.74, reflecting a daily decline of approximately 1.05%, per SID market data. Despite this short-term pullback, the stock has demonstrated meaningful momentum over broader timeframes, gaining 1.09% over the past month, 11.94% over three months, and 10.45% over the trailing twelve months. The stock currently trades well above its 200-day moving average of $554.76, representing a premium of approximately 24.9%, while also sitting above its 50-day moving average of $673.85. The 14-day relative strength index stands at 44.8, indicating the stock resides in neutral territory without overbought or oversold conditions, according to Massive/Polygon technical data. Average daily trading volume registers at approximately 2.05 million shares. The company's beta of 0.902 indicates slightly lower volatility relative to the broader market, consistent with Thermo Fisher's positioning as a large-cap Healthcare sector constituent with a market capitalization of approximately $219.4 billion.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific currently trades at a price-to-earnings ratio of 33.30, positioning the stock at a premium relative to the broader market, per SID market data. The company's price-to-book ratio stands at 4.29, reflecting the market's valuation of the firm's intangible assets, brand strength, and intellectual property portfolio within the life sciences and diagnostics space. The PEG ratio registers at an elevated 577.17, suggesting that earnings growth expectations remain modest relative to the current earnings multiple, according to SEC filings. The company maintains a dividend yield of approximately 0.29%, indicating that Thermo Fisher prioritizes capital reinvestment and strategic acquisitions over shareholder cash distributions. Within the Healthcare sector, these valuation metrics reflect the company's classification as a premium-priced, quality compounder. The $219.4 billion market capitalization underscores Thermo Fisher's status as one of the largest companies in the scientific instruments and laboratory equipment industry globally.
Smart Money Activity for TMO
Thermo Fisher Scientific registers a composite smart money score of 44, corresponding to a neutral signal, per SID market data. The institutional component stands at a perfect 25 out of 25, reflecting robust conviction from large asset managers and institutional holders. However, other smart money categories present a more cautious picture. The insider score sits at 8.9 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days, comprising 6 purchases and 14 sales. This sell-to-buy ratio of approximately 2.3-to-1 indicates a net disposition trend among corporate insiders. The dark pool activity score registers at 8.5 out of 25, suggesting limited notable accumulation through off-exchange channels. Congressional trading activity scores just 1.6 out of 25, reflecting minimal reported positions among members of Congress, according to 13F institutional filings and congressional disclosure records. The divergence between strong institutional support and weaker insider sentiment creates a mixed smart money profile for the stock.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific has demonstrated a consistent pattern of exceeding analyst expectations across its three most recent reported quarters, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $6.68 against a consensus estimate of $6.40, delivering a positive surprise of $0.28. The prior quarter produced EPS of $6.03 versus the $5.71 estimate, representing a beat of $0.32, the largest surprise in the current reporting cycle. The quarter before that showed EPS of $5.44 against a $5.23 estimate, a positive surprise of $0.21. This trajectory reveals sequential earnings growth from $5.44 to $6.03 to $6.68, reflecting quarter-over-quarter acceleration. The upcoming quarter carries an analyst consensus estimate of $5.71 per share, per analyst estimates. The consistent beat pattern across three consecutive quarters, with surprises ranging from $0.21 to $0.32, underscores management's ability to deliver results above market expectations.
Wall Street Analyst Ratings for TMO
Wall Street consensus on Thermo Fisher Scientific remains uniformly bullish, with all five most recent analyst actions reaffirming positive ratings, per Wall Street analyst reports. On October 30, 2026, Argus Research maintained its Buy rating on TMO. Following the company's earnings release, Citigroup reiterated a Buy rating on October 23, while both TD Cowen and Stifel maintained their Buy recommendations on October 22. Baird also reaffirmed its Outperform rating on October 22. Notably, none of these five analyst actions represented upgrades or downgrades; each maintained a prior bullish stance, indicating sustained conviction rather than a shift in sentiment. The clustering of four reaffirmations around October 22-23 aligns with the post-earnings review cycle, according to SID consensus data. The absence of any Hold, Underperform, or Sell ratings among recent coverage updates reflects broad agreement among major sell-side institutions regarding Thermo Fisher's fundamental positioning within the life sciences tools market.